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Abstract of thesis presented to the Senate of Universiti Putra Malaysia in 
fulfilment of the requirements for the degree of Doctor of Philosophy 
CYTOTOXIC EFFECTS OF METHYLGERAMBULLIN AND BIS­
(METHYLTHIOMETHYL)-DISULPHIDE (SB) ON T -L YMPHOBLASTIC 
LEUKEMIC CELL LINE (CEM-SS) 
By 
SHAR MARIAM MOHAMED 
August 2000 
Chairman: Associate Professor Abdul Manaf Ali, Ph.D. 
Faculty: Food Science and Biotechnology 
The cytotoxic effects of 2 sulphur-containing compounds were studied on T-
lymphoblastic leukemic cell line. Methylgerambullin is believed to be a new 
sulphone derived from a methylthiopropenoic acid isolated from Glycosmis 
calcicola (family Rutaceae). Another sui phonic compound IS bis-
(methylthiomethyl)-disulphide, an extract from Scorodocarpus borneensis 
(family Olacaceae) with irritating garlic-like odor. Cytotoxic activities of 
methylgerambullin and bis-(methylthiomethyl)-disulphide were tested against 
CEM-SS (T-Iymphoblastic leukaemia), KU812F (chronic myelogeneous 
leukaemia), UACC-62 (melanoma) and HT29 (colon cancer) cell lines using 
MTT, a colorimetric tetrazolium-based assay. Cytotoxic concentrations of the 
compounds that killed cells by 50% (CD50) with respect to untreated cell 
population, varied among the cell lines tested. CEM-SS was found to be the most 
sensitive cell line to methylgerambullin and bis-(methylthiomethyl)-disulphide 
with CD50 = 0.25 )lg/ml and 3.50 )lg/ml respectively. The cytotoxic effects 
exerted by both compounds on this cell line was studied from both morphological 
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manner over 72 hours period. Microscopic observations, including inverted 
microscopy of live cultures, fluorescent microscopy of acridine orange-propidium 
iodide stained cultures, and scanning and transmission electron microscopy 
showed that both necrotic and apoptotic death occurred in meiliylgerambullin­
and bis-(methylthiomethyl)-disulphide-treated cell populations, based on 
morphological criteria. From agarose gel electrophoresis and quantitative 
analyses of intemucleosomal cleavage, treatments with these compounds at their 
respective CD50 doses did not yield random or multiple of 180-200 bp DNA 
fragmentation which often associated with necrotic and apoptotic deaths 
respectively. Such observation may simply owe to the fact that the percentage of 
apoptosis and necrosis events were fairly low as quantified after acridine orange­
propidium iodide staining, or may also suggest the involvement of sulphur 
residue in methylgerambullin and bis-(methylthiomethyl)-disulphide which act as 
an antioxidant, thus protecting DNA degradation from occuring. Flow cytometric 
analyses based on annexin V-FITC (fluorescein isothiocynate) binding to the 
phosphatidylserines residue which was translocated from the inner to the outer 
leaflet of the plasma membrane showed that the onset of apoptosis in both 
methylgerambullin- and bis-(methylthiomethyl)-disulphide-treated population 
was at 6 hours exposure. Both methylgerambullin and bis-(methylthiomethyl)­
disulphide induced GO/G 1 arrest up to 48 hours and 24 hours respectively 
followed by arrest in the subsequent S phase. 
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Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai 
memenuhi keperluan untuk ijazah Doktor Falsafah. 
KESAN SITOTOKSIK OLEH METHYLGERAMBULLIN AND BIS­
(METHYLTHIOMETHYL)�DISULPHIDE (SB) KE ATAS SEL-SEL T­
LIMFOBLASTIK LEUKEMIA (CEM-SS) 
Oleh 
SHAR MARIAM MOHAMED 
Ogos 2000 
Pengerusi: Profesor Madya Dr. Abdul Manaf Ali 
Fakulti: Sains Makanan dan Bioteknologi 
Kesan sitotoksik oleh 2 sebatian yang mengandungi sulfur telah dikaji ke atas sel-
sel T-limfoblastik leukemia. Metilgerambullin, dipercayai satu sebatian sulfon 
yang terbaru ditemui adalah hasilan terbitan daripada asid metiltiopropenoik yang 
diekstrak daripada Glycosmis calcicola (keluarga Rutaceae). Satu lagi sebatian 
ialah bis-(metiltiometil)-disulfida yang diekstrak daripada Scorodocarpus 
borneensis (keluarga Olacaceae) yang berbau seperti bawang putih. Aktiviti 
sitotoksik metilgerambullin dan bis-(metiltiometil)-disulfida telah diuji ke atas 
sel-sel CEM-SS (T-limfoblastik leukemia), KU812F (kronik myelogeneous 
leukemia), UACC-62 (melanoma) dan HT29 (kanser kolon) menggunakan 
kaedah MTT yang bergantung kepada perubahan wama tetrazolium. Hasil kajian 
menunjukkan bahawa sel CEM-SS adalah sel yang paling sensitif terhadap 
metilgerambullin dan bis-(metiltiometil)-disulfida dengan kepekatan yang 
berupaya membunuh 50% daripada populasi sel (CD50) iaitu 0.25 Ilg!ml bagi 
metilgerambullin dan 3.50 Ilg!ml bagi bis-(metiltiometil)-disulfida. Kesan 
sitotoksik sebatian-sebatian ini dinilai melalui perubahan pada morfologi sel dan 
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perubahan di peringkat molekular selepas rawatan dengan sebatian-sebatian 
tersebut selama 72 jam. Penilaian mikroskopik termasuklah menggunakan 
mikroskop terbalikan ke atas kultura hidup, mikroskop floresen selepas 
pewamaan sel dengan akridin oren- propidium iodida dan mikroskopi elektron 
menunjukkan bahawa kematian apoptosis dan nekrosis berlaku di dalam populasi 
sel yang dirawat dengan metilgerambullin dan bis-(metiltiometil)-disulfida. 
Daripada keputusan yang diperolehi melalui elektroforesis pada jel agaros dan 
analisis kuantitatif pada belahan nukleosom, rawatan dengan kedua-dua sebatian 
pada dos CD50 masing-masing tidak menghasilkan belahan rawak atau belahan 
spesifik 180-200 bp pada DNA yang masing-masing dikaitkan dengan kematian 
nekrosis dan apoptosis. Pemerhatian tersebut mungkin disebabkan oleh peratusan 
kematian apoptosis dan nekrosis yang terlalu sedikit sepertimana yang telah 
dikenalpasti secara kuatitatif melalui kaedah pewamaan sel dengan akridin oren 
dan propidium iodida, atau mungkin disebabkan oleh kesan perlindungan sulfur 
yang terdapat pada methylgerambullin dan bis-(metiltiometil)-disulfida yang 
bertindak sebagai antioksidan yang melindungi daripada berlakunya belahan 
DNA. Analisis menggunakan flow saitometer berdasarkan pada ikatan annexin 
V-FITC (fluoresen isotiosianida) pada fosfatidilserine yang mengalami 
translokasi dari lapisan dalam ke lapisan luar membran plasma, menunjukkan 
bahawa kejadian apoptosis dalam populasi sel yang dirawat dengan 
methylgerambullin dan SB berlaku seawal 6 jam selepas rawatan. 
Methylgerambullin dan SB juga didapati berupaya merencatkan sel pada fasa 
GO/G 1 dalam kitaran sel hingga 48 jam dan 24 jam masing-masing selepas 
rawatan, diikuti dengan rencatan pasa fasa S dalam kitaran sel. 
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Screening for potential anticancer compounds has been one of the most 
important aspects in cancer research. Many commercially available drugs are 
synthetically derived, for example etoposide, a semi-synthetic 
epipodophyllotoxin that is one of the most commonly used anti-cancer drugs 
(Joel, 1996). Although these synthetic drugs are known to be very effective 
against cancer cells, they also possess some undesirable side effects such as 
neurotoxicity, fibrinolysis and ototoxicity (hearing loss) (Casciato and Lowitz, 
1995). Thus, choices for improvement are confined to introduce natural products 
as potential anticancer agents. Phytochemicals, one of these natural substances 
have been known to exhibit a wide variety of medicinal value ever since the 
ancient times. The scientific theories underlying their medicinal properties 
however remained unknown then. Wilkinson, (1998) recently highlighted that 
herbal products have great potential in the emerging nutraceutical and 
pharmaceutical industries in that they are widely consumed as food and are used 
in preventive and curative treatments throughout the world. It was reported in the 
same study that tropical forests have produced 47 major pharmaceutical drugs of 
world-wide importance and it is estimated that 328 potential drugs of major 
importance is yet to be discovered which would be worth $147 billion. The 
tropical forests still offers 125,000 flowering plant species that are of 
pharmacological relevance but this will involve 50,000 to one million screening 
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tests to discover one profitable drug, which seem to be the ultimate constraint in 
the discovery of new drugs. 
It has been reported by the Alliance Pharmaceutical Corporation that on average, 
12 years are needed for an experimental drug to be brought from the laboratory 
to the market shelf (Wierenga and Eaton, Internet). Preclinical testing requires 
three and a half years of experiments in laboratory on in vitro and animal models 
to assess safety and biological activities of the compound. Another six years are 
required for clinical trials that assess the safety, dosage, effectiveness and 
monitor the adverse reaction of the compound. Only five in 5000 compounds that 
enter preclinical testing make it to human testing. Approval process by the Food 
and Drug Administration (FDA) will take about two and a half years where 
normally only one of the five compounds tested in humans is approved. 
Despite the duration of time required to evaluate a potential drug, numerous 
phytochemicals have been scientifically isolated and their discovery was very 
much directed in the perspective of anticancer drug development. Plant 
constituents such as taxol, camptothecin, podophyllotoxin, vinblastine and 
vincristine represent some of the most important drugs currently utilized for the 
treatment of human cancers (Wall and Wani, 1993). Numerous more 
phytochemica1s are under investigations and have the potential to be on the 
pharmaceutical market shelves. Among these are betulinic acid, gonoithalamin 
and dammarane-type triterpenes, to name a few. Betulinic acid, which is 
available in abundant supply from the bark of white birch trees was reported to 
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be specific for inhibiting human melanomas (Pisha et al., 1995). 
Gonoiothalamin, isolated from various Gonoiothalamus sp. was found to be 
toxic to cervical, pancreas, gastric and breast carcinoma (Ali et al., 1996). 
Dammarane-type triterpenes from Cloeme africana has been shown to be highly 
toxic against leukemia (Nagaya et ai., 1997). 
One of the most extensively studied diseases is leukemia that remains to be a 
formidable disease. Due to the ease of obtaining repeated samples from blood, 
marrow or lymph nodes, most of the principles of cancer therapy is largely based 
on the leukemia model. Important breakthroughs in cancer therapy were 
achieved in the treatment of leukemia, which includes the use of combination 
therapy, immunotherapy, supportive therapy using antibiotics and blood product 
support and bone marrow transplant (Ng, 1996). Treatment with antileukaemic 
drugs however only controls the symptom without enhancing the survival rate 
(Arthur, 1989). Chemotherapeutic agents, also known as cytotoxins due to its 
ability to kill cells are normally less specific in that these agents kill not only 
cancer cell but also normal cells. Thus, the most apparent implication of 
chemotherapy is emanation of side effects which include hair loss, nausea, 
vomitting, constipation and can be as disastrous as myelosuppression (drop in 
blood count - neutropenia, thrombocytopenia, anaemia), and damage on cardiac, 
pulmonary, renal and hepatic systems (Ng, 1996). This prompted efforts to 
screen for antileukaemic agents that will have a dramatic cytotoxic effect 
specifically on the target cells. Most of the drugs currently used act via two 
distinct mechanisms: inhibition of cell proliferation or induction of active cell 
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death (Vial et al., 1997). Compounds that act via the latter mechanism are likely 
to be a better candidate as an antileukaemic agent because in the former action, 
some individual cells may have escaped through salvage pathways, and will 
continue to proliferate. The advancement in research techniques and the 
introduction of new molecular tools in recent years have prompted more efforts 
in investigations to build understanding on how exposure to the existing or newly 
discovered drugs lead to cell death. The efficacy of these drugs has been 
critically assessed by the many mechanisms of cell death and resistance that 
adversely limit their efficacy. Today, due to the urgent need for studies in various 
fields that closely mimics the animal systems, animal cell culture which was only 
an esoteric art during those time has become an established technology. New 
drug discovery, for example, may not be recognized and may be unsafe for use in 
man. Thus, pre-clinical trials are needed, which can be made possible with cell 
culture technology. 
It is thus crucial to determine the mode of action exerted by a potential 
anticancer agent. This has led to the design of the experimental approach which 
will be implemented in the current study. Both cellular and molecular changes in 
treated cell populations will be examined and compared with control (untreated) 
populations in a time course manner. Hence, either necrotic or apoptotic cell 
death could be suggested. Morphological studies may offer answers to whether 
physiological and accidental deaths are causally related and to the degree of 
overlapping between apoptotic and necrotic pathways. 
